Defence Therapeutics Inc. (CSE:DTC)

Market Cap	42.14M
Revenue (ttm)	n/a
Net Income (ttm)	-3.52M
Shares Out	54.73M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,900
Average Volume	58,344
Open	0.7800
Previous Close	0.8000
Day's Range	0.7700 - 0.7800
52-Week Range	0.4900 - 1.6400
Beta	1.32
RSI	45.75
Earnings Date	Nov 12, 2025

About Defence Therapeutics

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: DTC